Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 3/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876249 | 0.86 | ANPEP (0.39) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL4876777 | 0.84 | ANPEP (0.37) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL4868358 | 0.81 | ANPEP (0.36) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL403860 | 0.79 | ANPEP (0.35) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL4878757 | 0.76 | ITGB1 (0.36) | MMEACECPA1ACE2 | |
| SCHEMBL4873402 | 0.74 | ANPEP (0.36) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL403598 | 0.73 | ANPEP (0.35) | ANPEP | |
| SCHEMBL2157193 | 0.73 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL4877871 | 0.71 | PYGL (0.34) | — | |
| SCHEMBL404156 | 0.71 | MMP1 (0.38) | MMP1MMP3HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | MMP1 1000/4885MMP3 1396/4885HDAC3 2114/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | MMP1 1000/4885MMP3 1396/4885HDAC3 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.